Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
World Lung 2021 – front-line competition lines up behind Keytruda
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
World Lung 2021 preview – China challenges and tremelimumab rises
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Tori’s lung cancer hit raises a key question
The Junshi/Coherus drug only beat chemotherapy, and its study was run not in the US but in China.
No fast way to eighth place for Incyte
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Why not bapineuzumab?
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Asco 2021 – financial toxicity in the spotlight
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
